Novotek Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 19-12-2024
- Paid Up Capital ₹ 0.15 M
as on 19-12-2024
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2019
- Revenue %
(FY 2019)
- Profit -188.60%
(FY 2019)
- Ebitda -2488.90%
(FY 2019)
- Net Worth -79.86%
(FY 2019)
- Total Assets -8.74%
(FY 2019)
About Novotek Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Nileshkumar Shah, Jyotindra Raiyani, Roma Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230GJ2010PTC062760
- Company No.
062760
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Oct 2010
- Date of AGM
27 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Novotek Formulations?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nileshkumar Shah  | Director | 27-Oct-2010 | Current |
| Roma Shah | Director | 28-Dec-2012 | Current |
| Jyotindra Raiyani | Director | 28-Dec-2012 | Current |
| Arun Raiyani | Director | 28-Dec-2012 | Current |
| Rakshit Talaviya | Director | 28-Dec-2012 | Current |
Financial Performance of Novotek Formulations.
Novotek Formulations Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 188.6% decrease in profit. The company's net worth observed a substantial decline by a decrease of 79.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Novotek Formulations?
In 2019, Novotek Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Flowtech Measuring Instruments Private LimitedActive 13 years 7 monthsNileshkumar Shah and Roma Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Novotek Formulations?
Unlock and access historical data on people associated with Novotek Formulations, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Novotek Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novotek Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
